Shanghai Henlius Biotech (HKG:2696) dosed the first patient in an international multi-center phase 1 study of a HLX17 in the United States, according to a Friday Hong Kong bourse filing.
The trial is studying the drug in patients with multiple resected solid tumors.
A phase 1 trial of the drug is simultaneously being conducted in Mainland China.